GET DAILY SIGNALSNovartis (NVS): Q1 2026 Earnings Preview with +2.5% Sales Growth Expected
Key Takeaways
- Analysts forecast Q1 2026 revenue of approximately $13.6 billion, a modest 2.5% increase year-over-year.
- Consensus EPS estimate stands at $2.11 per share, reflecting steady profitability.
- Key focus on growth drivers like Kisqali, Cosentyx, and Entresto amid patent pressures.
- Q1 2025 saw 15% sales growth at constant currencies (cc), setting a high bar.
- Investors watching for updates on FY 2026 guidance navigating major patent expiries.
- Stock has historically risen 1.3% on average in the two weeks before earnings.
Earnings Context and Why It Matters
Novartis (NVS), a global leader in innovative medicines, enters Q1 2026 earnings with momentum from its priority brands amid a challenging pharma landscape. The company reported robust Q1 2025 results, with net sales up 15% at constant currencies and core operating income rising 27%, driven by strong demand for oncology and immunology drugs. FY 2025 delivered high single-digit sales growth, achieving a 40% core margin. In my view, this report matters because it will signal progress against 2026 goals, including growth through the largest patent expiry in company history, providing insights into pipeline execution and margin resilience for investors eyeing long-term value in healthcare.
Earnings Expectations
Wall Street anticipates Q1 2026 net sales of around $13.6 billion for NVS, up 2.5% from the prior year, with some estimates reaching $13.5-14.2 billion. Consensus EPS is pegged at $2.11-$2.13, building on Q1 2025's $2.28 core EPS growth of 31%. Investors are focused on core net sales growth (cc), expected in mid-single digits per ongoing trends, and core operating margin expansion toward 40%+. I also checked recent trends using Tickeron’s AI Trend Prediction Engine, which supports these expectations.
Key metrics include performance of top products: Kisqali (breast cancer), with peak sales potential over $10 billion and prior +56% growth; Cosentyx (immunology, +11%); and Entresto (heart failure), facing generic competition. Guidance updates for FY 2026, projecting sales CAGR of 5-6% through 2030, will be critical. Historically, NVS stock has reacted positively to beats on volume-driven growth from these franchises.
Market Reaction and Investor Sentiment
Heading into earnings, sentiment around NVS is cautiously optimistic, with shares trading around $145, near recent highs. The stock has gained modestly pre-earnings, aligning with historical patterns of +1.3% average move in the prior two weeks. Key risks include slower-than-expected growth in mature products like Entresto or delays in pipeline readouts. From what I see, a beat on core metrics could drive upside, while guidance reaffirmation would support stability.
One Tool I Use: Tickeron’s AI Screener
In my research on stocks like NVS, Tickeron’s AI Screener has become a go-to resource. This AI-powered stock and ETF discovery tool helps me filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. I can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, which is especially useful when comparing pharma peers.
Forward Outlook and Key Factors to Monitor
Following Q1 results, attention will shift to Novartis (NVS)'s FY 2026 guidance, particularly how it addresses the largest patent cliff in company history. The firm expects to sustain growth, backed by eight high-potential brands like Kisqali and Cosentyx with peak sales of $3-10 billion each. One thing that stands out is the potential for sales trends in immunology and oncology segments, where volume growth from new indications (e.g., Cosentyx in hidradenitis suppurativa) could offset pressures on cardiovascular drugs like Entresto.
Pipeline catalysts, including Pluvicto expansions and radioligand therapies, remain pivotal for long-term revenue diversification. Margin dynamics will be key, with core operating margins targeted above 40% amid cost discipline and R&D efficiency (R&D meaning research and development). Broader industry factors like U.S. pricing reforms and biosimilar competition could influence outlook. Upcoming events include Q2 results in July 2026. I’m watching this closely for signs of resilience.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
NVS in upward trend: 10-day moving average broke above 50-day moving average on October 22, 2026
The 10-day moving average for NVS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 45 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 188 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 20 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 18 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
NVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. NVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.437) is normal, around the industry mean (-1.421). P/E Ratio (24.370) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.117) as compared to the industry average of (0.038). P/S Ratio (4.715) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care and nutritional products
Industry PharmaceuticalsMajor
Advertisement